SGHT at a glance
Sight Sciences, Inc. (SGHT, SEC CIK 1531177) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and Form 4 insider filings as recently as November 18, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74.
- As of September 30, 2026, 25 institutional investment managers tracked by SignalX reported holding Sight Sciences, Inc. (SGHT) shares worth $90.7 million in 13F-HR filings.
- The most recent insider open-market sale reported on Form 4 was by Taylor Brenton on November 16, 2026 of 20,685 shares at $10.64 per share.
- In the last 90 days, SGHT insiders reported 0 open-market purchases ($0) and 6 open-market sales ($873K) on Form 4, a net sale of $873K.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $77.4M
- −3.1% vs prior year
- Insiders · 90 days
- 0 buys · 6 sells
- Net −$873K
- 13F holders
- 25 funds
- $90.7M · +1 vs prior quarter
- Latest 8-K
- Nov 4, 2026
- Item 2.02 · Item 7.01
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Sep 30, 2026
Management Discussion & Analysis
- Revenue $24.9M, up 25.2% YoY from $19.9M
- Interventional Dry Eye strongest growth: $3.9M revenue vs $0.2M, gross margin 79.0% vs 37.8%
- Interventional Glaucoma largest segment: $21.0M revenue, up 6.7% YoY
- Total gross margin 85.9% vs 86.4% YoY, operating loss $6.1M vs $7.9M
- Cash $77.4M; operating cash use $15.1M vs $27.9M, management expects liquidity beyond 12 months
Risk Factors
- No material changes to risk factors since the Annual Report
- Business, results, liquidity, and prospects vulnerable to identified or currently unknown risks
- Common-stock trading price could decline, potentially causing total or partial investment loss
AI summary of the SGHT 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q3 2026 results announced for quarter ended September 30, 2026
- Full-year 2026 revenue guidance raised, signaling improved expected sales performance
Item 7.01: Regulation FD Disclosure
- Investor presentation posted November 4, 2026, intended for investor and analyst communications
- Exhibit 99.2 contains the presentation, potentially including updated strategy, operating metrics, or financial guidance
Item EX-99.1: Item EX-99.1
- Q3 revenue $24.9M, up 25% year over year, signaling accelerating commercial traction
- IDE revenue $3.9M versus $0.2M, with 222 active customers and 4,581 treatment units sold
Item EX-99.2: Item EX-99.2
- Q3 2026 revenue $24.9M, up 25% YoY, marking a third consecutive quarter of double-digit growth
- FY2026 revenue guidance $92M-$93M, up 19%-20% YoY, signaling accelerating commercial momentum
Item 5.02: Departure/Appointment of Directors or Principal Officers
- Kashif Rashid appointed Chief Legal Officer and Corporate Secretary effective August 10, 2026
- $450,000 base salary and 50% target annual cash bonus
Item EX-99.1: Item EX-99.1
- Q2 revenue $23.4M, up 20% YoY; glaucoma revenue rose 8% while dry-eye revenue surged 704% to $2.7M
- Gross margin reached 91.4%, with dry-eye margin improving to 84.7% from 38.4% YoY
Item 7.01: Regulation FD Disclosure
- Investor presentation posted August 5, 2026 under Regulation FD
- Exhibit 99.2 contains materials management expects to use with investors and analysts
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results announced for quarter ended June 30, 2026
- 2026 revenue guidance raised, signaling stronger expected sales performance
Item EX-99.2: Item EX-99.2
- FY2026 revenue guidance: $88M-$92M, implying return to double-digit growth and approximately 13% CAGR from FY2021
- Q2 2026 revenue growth: 20% year over year, supporting the company’s projected growth recovery
AI summaries of SGHT 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for SGHT
Don't miss the next SGHT filing
- Alerts as it files. A push when SGHT files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut SGHT, by share count.
- Ask anything. An AI agent that reads every SGHT filing and answers with sources.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Taylor Brenton | Sell | Nov 16, 2026 | 20,685 | $10.64 |
| Bauerlein Alison | Sell | Oct 2, 2026 | 25,260 | $8.85 |
| Taylor Brenton | Sell | Oct 2, 2026 | 2,988 | $8.85 |
| Rodberg James | Sell | Oct 2, 2026 | 7,208 | $8.85 |
| Badawi David | Sell | Oct 1, 2026 | 7,797 | $9.05 |
| Badawi Paul | Sell | Oct 1, 2026 | 29,653 | $9.05 |
| Rashid Kashif | A | Aug 10, 2026 | 181,818 | - |
| HAYDEN JEREMY B. | Sell | Jul 6, 2026 | 12,733 | $5.51 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $79.9M | $77.4M |
| Gross Profit | - | $68.3M | $66.7M |
| Operating Income | - | -$50.5M | -$37.1M |
| Net Income | - | -$51.5M | -$38.4M |
| Gross Margin | - | 85.5% | 86.2% |
| Op. Margin | - | -63.3% | -48.0% |
| Net Margin | - | -64.5% | -49.7% |
| Balance Sheet | |||
| Total Assets | $166.7M | $142.8M | $115.3M |
| Equity | $120.2M | $87.5M | $63.9M |
| ROE | - | -58.8% | -60.1% |
| Per Share | |||
| EPS | - | $-1.03 | $-0.74 |
| Cash Flow | |||
| Operating CF | - | -$22.4M | -$29.7M |
| CapEx | - | $385K | $224K |
Source: XBRL data in Sight Sciences, Inc. (SGHT)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
13F Fund Holdings: Quarterly Trend
Latest: Q3 2026Aggregate SGHT share value held by 13F filers tracked by SignalX, by quarter.
Quarterly totals table
| Quarter | Funds | Total value |
|---|---|---|
| Q3 2026 | 25 | $90.7M |
| Q2 2026 | 24 | $45.7M |
| Q1 2026 | 25 | $30.1M |
| Q4 2025 | 23 | $66.7M |
| Q3 2025 | 20 | $25.6M |
| Q2 2025 | 20 | $30.5M |
| Q1 2025 | 18 | $13.9M |
| Q4 2024 | 13 | $15.4M |
- Millennium Management+634.1K (+842%)
- BlackRock+278.1K (+9%)
- Invesco Ltd+192.9K (+907%)
- Goldman Sachs Group+77.9K (+39%)
- D.E. Shaw & Co+69.1K (+25%)
- AQR Capital Management−119.1K (-30%)
- Citadel Advisors LLC−89.7K (-41%)
- Wells Fargo & Co−23.9K (-67%)
- Renaissance Technologies LLC−16.8K (-8%)
- Citigroup−16.5K (-89%)
- Prudential Financial+47.6K
- Principal Financial Group+10.8K
- FMR LLC (Fidelity)−7.9K
Source: 13F-HR filings on SEC EDGAR (aggregated from 168 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work
SGHT filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-Q quarterly reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 4 | Nov 18, 2026 | - | - | - |
| 8-K | Nov 4, 2026 | - | Analysis | - |
| 10-Q | Nov 4, 2026 | Sep 30, 2026 | Analysis | |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Oct 5, 2026 | - | - | - |
| 4 | Aug 18, 2026 | - | - | - |
| 8-K | Aug 10, 2026 | - | Analysis | - |
| 8-K | Aug 5, 2026 | - | Analysis | - |
| 10-Q | Aug 5, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jul 6, 2026 | - | - | - |
| 4 | Jun 11, 2026 | - | - | - |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 4 | Jun 5, 2026 | - | - | |
| 8-K | Jun 5, 2026 | - | Analysis |
Related Health Care companies
- ARAY · ACCURAY INCSurgical & Medical Instruments & Apparatus
- ATEC · Alphatec Holdings, Inc.Surgical & Medical Instruments & Apparatus
- ANGO · ANGIODYNAMICS INCSurgical & Medical Instruments & Apparatus
- ANIK · Anika Therapeutics, Inc.Surgical & Medical Instruments & Apparatus
- AORT · ARTIVION, INC.Surgical & Medical Instruments & Apparatus
- ATRC · AtriCure, Inc.Surgical & Medical Instruments & Apparatus
- RCEL · AVITA Medical, Inc.Surgical & Medical Instruments & Apparatus
- BAX · Baxter InternationalSurgical & Medical Instruments & Apparatus
SGHT SEC filings: frequently asked questions
Are SGHT insiders buying or selling?
In the last 90 days, Sight Sciences, Inc. (SGHT) officers, directors and 10% owners reported no open-market purchases and 6 open-market sales worth $872,783 by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
Which institutions hold SGHT stock?
As of September 30, 2026, the largest Sight Sciences, Inc. (SGHT) holders among the 13F filers tracked by SignalX were BlackRock ($31.5 million), Vanguard Capital Management LLC ($15.3 million), State Street Corp ($7.9 million), Millennium Management ($6.6 million), Dimensional Fund Advisors ($3.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.
What was SGHT's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Sight Sciences, Inc. (SGHT) reported revenue of $77.4 million (down 3.1% from FY2024) and a net loss of $38.4 million. Diluted EPS was -$0.74. The figures come from the XBRL data in the 10-K.
What did SGHT report in its latest 8-K?
Sight Sciences, Inc. (SGHT) filed an 8-K on November 4, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). Q3 2026 results announced for quarter ended September 30, 2026.
What are the latest SGHT SEC filings?
Sight Sciences, Inc. (SGHT) filed its latest 10-K annual report on March 4, 2026, a 10-Q quarterly report on November 4, 2026, an 8-K current report on November 4, 2026 and a Form 4 insider filing on November 18, 2026.
What is SGHT's SEC CIK number?
Sight Sciences, Inc. (SGHT)'s SEC Central Index Key (CIK) is 1531177. EDGAR lists every SGHT filing under that number.
Ask anything about SGHT
The research agent reads SGHT's filings, financials, insider trades and 13F holders, then answers with sources.